Latest & greatest articles for Uterine Fibroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Uterine Fibroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Uterine Fibroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Uterine Fibroid

1. Fibristal - ulipristal acetate - Uterine fibroids (signs and symptoms)

Fibristal - ulipristal acetate - Uterine fibroids (signs and symptoms) ulipristal acetate | CADTH.ca Find the information you need ulipristal acetate ulipristal acetate Last Updated: August 1, 2019 Result type: Reports Project Number: SF0609-000 Product Line: Generic Name: ulipristal acetate Brand Name: Fibristal Manufacturer: Allergan Inc. Indications: Uterine fibroids (signs and symptoms) Submission Type: Request For Advice Project Status: Complete Biosimilar: No Companion Diagnostics (...) : No Date Recommendation Issued: July 24, 2019 Recommendation Type: Reimburse with clinical criteria and/or conditions Key Milestones 1 Call for patient input posted March 29, 2019 Patient group input closed May 21, 2019 Clarification: - Patient input submission received from CANFib (Canadian Women with Fibroids Incorporated) and the Women’s Health Initiative Network Patient input summary sent for review to patient input groups May 14, 2019 Patient group comments on input summary closed May 21, 2019

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

2. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids Ultr Ultrasound-guided high-intensity tr asound-guided high-intensity transcutaneous anscutaneous focused ultr focused ultrasound for symptomatic uterine asound for symptomatic uterine fibroids fibroids Interventional procedures guidance Published: 24 July 2019 www.nice.org.uk/guidance/ipg657 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after (...) Recommendations Recommendations 1.1 Current evidence on the safety of ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 5efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

3. Effect of radiofrequency ablation on the treatment of uterine fibroid and a postprocedural inpatient hospitalization: a systematic review and meta analysis

Effect of radiofrequency ablation on the treatment of uterine fibroid and a postprocedural inpatient hospitalization: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

4. Uterine fibroids

Uterine fibroids Uterine fibroids - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Uterine fibroids Last reviewed: February 2019 Last updated: September 2018 Summary Most common benign uterine tumour. Most are asymptomatic; however, can present with excessive uterine bleeding, symptoms secondary to pressure on bladder and rectum, and, less often, distortion of the uterine cavity, leading to miscarriage or infertility (...) , or symptomatic management with non-steroidal anti-inflammatory drugs (NSAIDs). Definition Uterine fibroids (leiomyomata) are benign tumours of the uterus primarily composed of smooth muscle and fibrous connective tissue. Breech LL, Rock JA. Leiomyomata uteri and myomectomy. In: Rock JA, Jones III HW, eds. Te Linde's operative gynecology, 9th edition. Philadelphia, PA: JB Lippincott Co.; 2003:753-98. They range in size from seedlings to large uterine tumours. Grossly, these tumours are round, firm, and well

2018 BMJ Best Practice

5. FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids

FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids - Faculty of Sexual and Reproductive Healthcare FSRH CEU response to European Medicines Agency recommendations regarding use of ulipristal acetate for management of uterine fibroids FSRH CEU response to European Medicines Agency (...) recommendations regarding use of ulipristal acetate for management of uterine fibroids Share this article Published on: 12 February 2018 File size: 225kb PDF File type: Clinical Statements The European Medicines Agency (EMA) is currently reviewing the safety of use of Esmya® (ulipristal acetate) for management of uterine fibroids. This review follows reports of a very small number of cases worldwide of serious liver injury in women using Esmya. Until the review process is complete, temporary restrictions have

2018 Faculty of Sexual & Reproductive Healthcare

6. Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users

Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users - GOV.UK GOV.UK uses cookies to make the site simpler. Search Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users Temporary safety (...) measures are in place while an EU review investigates the link between cases of serious liver injury, including 4 cases requiring liver transplantation, and Esmya for uterine fibroids. Published 8 March 2018 From: Therapeutic area: , Contents Post-publication note This advice has now been superseded. The EU review restricted the indicated population for Esmya for safety reasons and introduced measures to minimise risk of liver injury. In particular, more than one treatment course is now authorised only

2018 MHRA Drug Safety Update

7. Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing

Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing | European Medicines Agency Search Search Menu Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing Press release 09/02/2018 No new patients should start treatment for the time being European Medicines Agency's (EMA) ( ) is currently reviewing the benefits (...) and risks with Esmya, following reports of serious liver injury, including liver failure leading to transplantation. As a temporary measure while the review is ongoing, the has recommended regular liver monitoring for women taking Esmya for uterine fibroids. All women taking Esmya should have a liver function test at least once a month during treatment. If the test is abnormal (liver enzyme levels more than 2 times the upper limit of normal), the healthcare professional should stop treatment and closely

2018 European Medicines Agency - EPARs

8. Uterine fibroids

Uterine fibroids Uterine fibroids - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Uterine fibroids Last reviewed: February 2019 Last updated: September 2018 Summary Most common benign uterine tumour. Most are asymptomatic; however, can present with excessive uterine bleeding, symptoms secondary to pressure on bladder and rectum, and, less often, distortion of the uterine cavity, leading to miscarriage or infertility (...) , or symptomatic management with non-steroidal anti-inflammatory drugs (NSAIDs). Definition Uterine fibroids (leiomyomata) are benign tumours of the uterus primarily composed of smooth muscle and fibrous connective tissue. Breech LL, Rock JA. Leiomyomata uteri and myomectomy. In: Rock JA, Jones III HW, eds. Te Linde's operative gynecology, 9th edition. Philadelphia, PA: JB Lippincott Co.; 2003:753-98. They range in size from seedlings to large uterine tumours. Grossly, these tumours are round, firm, and well

2018 BMJ Best Practice

9. Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids

Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids 1 Translation of the executive summary of the assessment of potential Magnetresonanztomografie-gesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms (Version 1.0; Status: 28 May 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive (...) Summary IQWiG Reports – Commission No. E14-04 Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids 1 Executive summary of assessment of potential E14-04 Version 1.0 High-intensity focused ultrasound therapy for uterine fibroids 28 May 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Magnetic resonance imaging-guided high-intensity focused ultrasound

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Ultrasound-guided high-intensity focused ultrasound for uterine fibroids ? Assessment according to §137h Social Code Book V

Ultrasound-guided high-intensity focused ultrasound for uterine fibroids ? Assessment according to §137h Social Code Book V 1 Translation of the executive summary of the assessment according to § 137h Social Code Book (SGB) V Sonografiegesteuerte hochfokussierte Ultraschalltherapie beim Leiomyom des Uterus (Version 1.0; Status: 30 January 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. H16-02B Ultrasound-guided high- intensity focused ultrasound therapy for uterine fibroids 1 Executive summary of assessment H16-02B according to §137h SGB V Version 1.0 USgHIFU for uterine fibroids 30 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ultrasound-guided high-intensity focused ultrasound

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Preoperative medical therapy before surgery for uterine fibroids. (PubMed)

Preoperative medical therapy before surgery for uterine fibroids. Uterine fibroids occur in up to 40% of women aged over 35 years. Some are asymptomatic, but up to 50% cause symptoms that warrant therapy. Symptoms include anaemia caused by heavy menstrual bleeding, pelvic pain, dysmenorrhoea, infertility and low quality of life. Surgery is the first choice of treatment. In recent years, medical therapies have been used before surgery to improve intraoperative and postoperative outcomes. However (...) ), and four compared SPRMs with placebo. Most results provided low-quality evidence due to limitations in study design (poor reporting of randomisation procedures, lack of blinding), imprecision and inconsistency. GnRHa versus no treatment or placebo GnRHa treatments were associated with reductions in both uterine (MD -175 mL, 95% CI -219.0 to -131.7; 13 studies; 858 participants; I² = 67%; low-quality evidence) and fibroid volume (heterogeneous studies, MD 5.7 mL to 155.4 mL), and increased preoperative

Full Text available with Trip Pro

2017 Cochrane

12. Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy

Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) . Laparoscopic electromechanical morcellation of uterine fibroids during myomectomy orhysterectomy. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Uterine fibroids, also known as myomas or leiomyomas, are benign tumors originating in the myometrium. Laparoscopic electromechanical morcellation of uterine fibroids involves the use of mechanically powered cutting devices to break up fibroid tissue for removal during minimally invasive myomectomy or hysterectomy. For standard laparoscopic

2017 Health Technology Assessment (HTA) Database.

13. [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]

[Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms: Potenzialbewertung; Auftrag E14-04 [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms: Potenzialbewertung; Auftrag E14-04 [Magnetic resonance (...) imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des

2017 Health Technology Assessment (HTA) Database.

14. [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids]

[Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms: Potenzialbewertung; Auftrag E14-05 [Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms: Potenzialbewertung; Auftrag E14-05 [Magnetic resonance (...) imaging-guided high-intensity focused ultrasound therapy for uterine fibroids] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Magnetresonanztomografiegesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des

2017 Health Technology Assessment (HTA) Database.

15. [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - addendum to commission H16-02B]

[Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - addendum to commission H16-02B] Sonografiegesteuerte hochfokussierte ultraschalltherapie beim leiomyom des uterus: addendum zum auftrag H16-02B; auftrag H17-01 [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids – addendum to commission H16-02B] Sonografiegesteuerte hochfokussierte ultraschalltherapie beim leiomyom des uterus: addendum zum auftrag H16-02B; auftrag H17-01 [Ultrasound-guided high (...) -intensity focused ultrasound for uterine fibroids – addendum to commission H16-02B] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sonografiegesteuerte hochfokussierte ultraschalltherapie beim leiomyom des uterus

2017 Health Technology Assessment (HTA) Database.

16. Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to õ137h Social Code Book V

Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to õ137h Social Code Book V Sonografiegesteuerte hochfokussierte Ultraschalltherapie beim Leiomyom des Uterus: Bewertungen gemäß § 137h SGB V; Auftrag H16-02B [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to §137h Social Code Book V] Sonografiegesteuerte hochfokussierte Ultraschalltherapie beim Leiomyom des Uterus: Bewertungen gemäß § 137h SGB V (...) ; Auftrag H16-02B [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to §137h Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sonografiegesteuerte

2017 Health Technology Assessment (HTA) Database.

17. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. (PubMed)

Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Uterine fibroids are smooth muscle tumours arising from the uterus. These tumours, although benign, are commonly associated with abnormal uterine bleeding, bulk symptoms and reproductive dysfunction. The importance of progesterone in fibroid pathogenesis supports selective progesterone receptor modulators (SPRMs) as effective treatment. Both biochemical and clinical evidence suggests that SPRMs may reduce fibroid growth (...) of 1215 study participants. We could not extract complete data from three studies. We included in the meta-analysis 11 studies involving 1021 study participants: 685 received SPRMs and 336 were given a control intervention (placebo or leuprolide). Investigators evaluated three SPRMs: mifepristone (five studies), ulipristal acetate (four studies) and asoprisnil (two studies). The primary outcome was change in fibroid-related symptoms (symptom severity, health-related quality of life, abnormal uterine

2017 Cochrane

18. Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000 InSightec Ltd.) for ablation of uterine fibroids

Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000 InSightec Ltd.) for ablation of uterine fibroids Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000; InSightec Ltd.) for ablation of uterine fibroids Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000; InSightec Ltd.) for ablation of uterine fibroids HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation HAYES, Inc.. Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000; InSightec Ltd.) for ablation of uterine fibroids. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' objectives Description of Technology: Magnetic resonance–guided focused ultrasound (MRgFUS) combines thermal effects (due to absorption of acoustic energy) with magnetic resonance imaging to treat symptomatic uterine fibroids. Thermal ablation

2017 Health Technology Assessment (HTA) Database.

19. Laparoscopic radiofrequency volumetric thermal ablation (Acessa System Halt Medical Inc.) for treatment of uterine fibroids

Laparoscopic radiofrequency volumetric thermal ablation (Acessa System Halt Medical Inc.) for treatment of uterine fibroids Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Uterine fibroids (also called leiomyomata or myomas) are common benign tumors of the myometrium, the smooth muscle layer of the uterus. They can produce pain, pressure, frequent and heavy bleeding

2017 Health Technology Assessment (HTA) Database.

20. Hysteroscopic morcellation for treatment of uterine submucosal fibroids and endometrial polyps

Hysteroscopic morcellation for treatment of uterine submucosal fibroids and endometrial polyps Hysteroscopic morcellation for treatment of uterine submucosal fibroids and endometrial polyps Hysteroscopic morcellation for treatment of uterine submucosal fibroids and endometrial polyps HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc (...) . Hysteroscopic morcellation for treatment of uterine submucosal fibroids and endometrial polyps. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2016 Authors' objectives Uterine fibroids account for nearly 40% of the approximately 600,000 hysterectomies performed each year in the United States. Endometrial polyps are also a common cause of abnormal uterine bleeding; they are found in 10% to 40% of symptomatic women, and in up to 12% of asymptomatic women. Description of Technology

2017 Health Technology Assessment (HTA) Database.